Eli Lilly to spin off animal health unit, quarterly profit beats estimates
Eli Lilly and Co announced on Tuesday it would spin off its Elanco animal health business and posted better-than-expected quarterly profit, helped by demand for its diabetes drugs Trulicity and Humalog. (Source: Reuters: Health)
Source: Reuters: Health - July 24, 2018 Category: Consumer Health News Tags: healthNews Source Type: news

Eli Lilly spins off animal health unit, second quarter beats
Eli Lilly and Co on Tuesday said it would spin off its Elanco animal health business into a publicly-traded company and posted better-than-expected quarterly profit helped by demand for its diabetes drugs Trulicity and Humalog. (Source: Reuters: Health)
Source: Reuters: Health - July 24, 2018 Category: Consumer Health News Tags: healthNews Source Type: news

Beta Bionics wins FDA nod for home-use trial of artificial pancreas tech
Beta Bionics said this week that it won FDA approval to start recruiting patients with Type I diabetes for home-use studies of its iLet bionic pancreas system. The trial is slated to test Novo Nordisk’s fast-acting insulin, Fiasp, with the company’s autonomous infusion pump in adults with Type I diabetes. The study will also evaluate insulin lispro and conventional insulin aspart combined with the iLet system in adults and kids with Type I diabetes, according to Beta Bionics. Get the full story at our sister site, Drug Delivery Business News. The post Beta Bionics wins FDA nod for home-use trial of artificial p...
Source: Mass Device - May 23, 2018 Category: Medical Devices Authors: Sarah Faulkner Tags: Diabetes Drug-Device Combinations Food & Drug Administration (FDA) Pharmaceuticals Beta Bionics Eli Lilly & Co. Novo Nordisk Source Type: news

Combining AI and CGM to Make a Bionic Pancreas
A startup company is combining artificial intelligence (AI) and glucose monitoring to develop what is being called a bionic pancreas. Beta Bionics has received FDA approval to begin recruitment for the home-use studies testing an insulin-only configuration of the iLet bionic pancreas system. The U.S.-based multicenter, multi-arm, cross-over, clinical will test Novo Nordisk’s recently approved, insulin called Fiasp with the iLet bionic pancreas system in adults with type 1 diabetes, and insulin lispro and conventional insulin aspart using the iLet in adults and children with type 1 diabetes. “The device is about the siz...
Source: MDDI - May 22, 2018 Category: Medical Devices Authors: Omar Ford Tags: Digital Health Source Type: news

Admelog (Insulin Lispro Injection) - new on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - December 21, 2017 Category: Drugs & Pharmacology Source Type: news

Companion Medical launches smart insulin pen in U.S.
Companion Medical started selling its smart insulin pen in the U.S. today, according to the San Diego, Calif.-based company. The InPen system, which combines an insulin injector pen and a smartphone app, is compatible with Eli Lilly‘s (NYSE:LLY) Humalog and Novo Nordisk‘s (NYSE:NVO) Novolog fast-acting insulin. Get the full story at our sister site, Drug Delivery Business News. The post Companion Medical launches smart insulin pen in U.S. appeared first on MassDevice. (Source: Mass Device)
Source: Mass Device - December 14, 2017 Category: Medical Devices Authors: Sarah Faulkner Tags: Diabetes Drug-Device Combinations mHealth (Mobile Health) Pharmaceuticals Companion Medical Eli Lilly & Co. Novo Nordisk Source Type: news

FDA Approves " Follow-On " Human Insulin Product to Treat Diabetes
Another short-acting insulin lispro injection has been approved by the FDA to treat adults and children with diabetes. The drug, marketed as Admelog, is... (Source: Physician's First Watch current issue)
Source: Physician's First Watch current issue - December 12, 2017 Category: Primary Care Source Type: news

FDA Approves New Human Insulin Product to Treat Diabetes
The short-acting insulin lispro injection has been granted final approval from the FDA to treat adults with type 2 diabetes and adults and children... (Source: Physician's First Watch current issue)
Source: Physician's First Watch current issue - December 12, 2017 Category: Primary Care Source Type: news

First Humalog Copycat (Admelog) Approved by FDA First Humalog Copycat (Admelog) Approved by FDA
Sanofi-Aventis ' Admelog approved for both diabetes types, and for use via injection or insulin pump.FDA Approvals (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - December 11, 2017 Category: Consumer Health News Tags: Diabetes & Endocrinology News Alert Source Type: news

FDA approves Sanofi ’s short-acting insulin lispro injection
The FDA today approved Sanofi‘s (NYSE:SNY) Admelog insulin lispro injection. The product is indicated to help adults and kids with Type I and Type II diabetes control their blood sugar levels. Admelog is the first short-acting insulin approved using the FDA’s 505(b)(2) pathway. Get the full story at our sister site, Drug Delivery Business News. The post FDA approves Sanofi’s short-acting insulin lispro injection appeared first on MassDevice. (Source: Mass Device)
Source: Mass Device - December 11, 2017 Category: Medical Devices Authors: Sarah Faulkner Tags: Diabetes Drug-Device Combinations Food & Drug Administration (FDA) Pharmaceuticals Regulatory/Compliance Wall Street Beat Sanofi-Aventis Source Type: news

FDA Approves Admelog (insulin lispro) Rapid-Acting " Follow-On " Insulin Product to Treat Diabetes
December 11, 2017 -- The U.S. Food and Drug Administration today approved Admelog (insulin lispro injection), a rapid-acting insulin indicated to improve control in blood sugar levels in adults and pediatric patients aged 3 years and older with type... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - December 11, 2017 Category: Drugs & Pharmacology Source Type: news

FDA Approves Admelog (insulin lispro) Short-Acting " Follow-On " Insulin Product to Treat Diabetes
December 11, 2017 -- The U.S. Food and Drug Administration today approved Admelog (insulin lispro injection), a short-acting insulin indicated to improve control in blood sugar levels in adults and pediatric patients aged 3 years and older with type... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - December 11, 2017 Category: Drugs & Pharmacology Source Type: news

FDA OKs Sanofi's follow-on biologic of Lilly's diabetes drug Humalog
(Reuters) - The U.S. Food and Drug Administration said on Monday it approved Sanofi SA's Admelog as the first follow-on biologic version of Eli Lilly and Co's fast-acting insulin, Humalog. (Source: Reuters: Health)
Source: Reuters: Health - December 11, 2017 Category: Consumer Health News Tags: healthNews Source Type: news

FDA Says'Yes' to Short-Acting Insulin Admelog
(MedPage Today) -- Final approval for Sanofi follow-on to Humalog confirms September 2017 tentative okay (Source: MedPage Today Public Health)
Source: MedPage Today Public Health - December 11, 2017 Category: American Health Source Type: news

FDA clears Sanofi's follow-on diabetes biologic of Lilly's Humalog
(Reuters) - The U.S. Food and Drug Administration said on Monday it approved Sanofi SA's Admelog as the first follow-on biologic version of Eli Lilly and Co's fast-acting insulin, Humalog. (Source: Reuters: Health)
Source: Reuters: Health - December 11, 2017 Category: Consumer Health News Tags: healthNews Source Type: news